Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
14
03
2023
accepted:
21
06
2023
medline:
30
10
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection. COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver disease (AILD) (n = 120; 77% mRNA and 23% viral vaccine), post-liver transplant (LT) (n = 146; 96% mRNA and 3% viral vaccine), and healthy controls (n = 51; 72% mRNA, 24% viral and 4% heterologous combination). Serological end points were measured, and data regarding breakthrough SARS-CoV-2 infection were collected. After adjusting by age, sex, and time of sample collection, anti-Spike IgG levels were the lowest in post-LT patients compared to cirrhosis (p < 0.0001), AILD (p < 0.0001), and control (p = 0.002). Factors predicting reduced responses included older age, Child-Turcotte-Pugh B/C, and elevated IL-6 in cirrhosis; non-mRNA vaccine in AILD; and coronary artery disease, use of mycophenolate and dysregulated B-call activating factor, and lymphotoxin-α levels in LT. Incident infection occurred in 6.6%, 10.6%, 7.4%, and 15.6% of cirrhosis, AILD, post-LT, and control, respectively. The only independent factor predicting infection in cirrhosis was low albumin level. LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level.
Sections du résumé
BACKGROUND
Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection.
METHODS
COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver disease (AILD) (n = 120; 77% mRNA and 23% viral vaccine), post-liver transplant (LT) (n = 146; 96% mRNA and 3% viral vaccine), and healthy controls (n = 51; 72% mRNA, 24% viral and 4% heterologous combination). Serological end points were measured, and data regarding breakthrough SARS-CoV-2 infection were collected.
RESULTS
After adjusting by age, sex, and time of sample collection, anti-Spike IgG levels were the lowest in post-LT patients compared to cirrhosis (p < 0.0001), AILD (p < 0.0001), and control (p = 0.002). Factors predicting reduced responses included older age, Child-Turcotte-Pugh B/C, and elevated IL-6 in cirrhosis; non-mRNA vaccine in AILD; and coronary artery disease, use of mycophenolate and dysregulated B-call activating factor, and lymphotoxin-α levels in LT. Incident infection occurred in 6.6%, 10.6%, 7.4%, and 15.6% of cirrhosis, AILD, post-LT, and control, respectively. The only independent factor predicting infection in cirrhosis was low albumin level.
CONCLUSIONS
LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level.
Identifiants
pubmed: 37870985
doi: 10.1097/HC9.0000000000000273
pii: 02009842-202311010-00008
pmc: PMC10586829
pii:
doi:
Substances chimiques
Albumins
0
COVID-19 Vaccines
0
RNA, Messenger
0
Viral Vaccines
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
Hepatology. 2022 Jul;76(1):126-138
pubmed: 35023206
J Immunol. 2010 Aug 1;185(3):1375-8
pubmed: 20601598
J Clin Invest. 2014 Jul;124(7):3147-58
pubmed: 24911151
Hepatol Int. 2022 Jun;16(3):691-701
pubmed: 35403977
Immunity. 2015 Dec 15;43(6):1186-98
pubmed: 26682988
JHEP Rep. 2022 Jul;4(7):100496
pubmed: 35502229
Dig Liver Dis. 2023 Feb;55(2):160-168
pubmed: 36266209
Nat Commun. 2016 Jan 08;7:10369
pubmed: 26742691
J Autoimmun. 2022 Oct;132:102906
pubmed: 36088883
Dig Liver Dis. 2023 Mar;55(3):316-321
pubmed: 36529636
Gastroenterology. 2019 Jul;157(1):149-162
pubmed: 30905652
Vaccines (Basel). 2021 Jul 04;9(7):
pubmed: 34358154
J Infect Dis. 2017 Jul 15;216(2):191-197
pubmed: 28838148
Immun Ageing. 2022 May 26;19(1):26
pubmed: 35619117
Vaccine. 2003 Sep 8;21(25-26):3826-36
pubmed: 12922116
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Methods Mol Biol. 2020;2099:107-116
pubmed: 31883091
JHEP Rep. 2023 Apr 26;:100776
pubmed: 37360567
J Allergy Clin Immunol. 2018 Sep;142(3):844-856
pubmed: 29155150
EBioMedicine. 2022 Aug;82:104166
pubmed: 35843172
Vaccines (Basel). 2021 Dec 01;9(12):
pubmed: 34960168
Vaccines (Basel). 2022 Jun 27;10(7):
pubmed: 35891193
Vaccine. 2015 Jun 8;33 Suppl 2:B55-9
pubmed: 26022570
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
J Hepatol. 2021 Dec;75(6):1434-1439
pubmed: 34454993
Am J Transplant. 2021 Dec;21(12):3971-3979
pubmed: 34291552
Immunol Rev. 2009 May;229(1):152-72
pubmed: 19426221
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
J Hepatol. 2022 Oct;77(4):1161-1197
pubmed: 35868584
Vaccine. 2018 Oct 8;36(42):6282-6289
pubmed: 30205979
J Hepatol. 2021 Aug;75(2):435-438
pubmed: 33892006
J Hepatol. 2021 Aug;75(2):439-441
pubmed: 33905793
Viruses. 2022 Jan 21;14(2):
pubmed: 35215801
Hepatol Int. 2022 Aug;16(4):755-774
pubmed: 35767172
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Vaccines (Basel). 2022 Feb 28;10(3):
pubmed: 35335009